CCEL Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 4.49% compared to Cryo-Cell International's net margin of 1.08%. Cryo-Cell International's return on equity of -- beat Astrana Health's return on equity of 7.09%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 73.12%. On the other hand Astrana Health has an analysts' consensus of $47.4444 which suggests that it could grow by 87.68%. Given that Astrana Health has higher upside potential than Cryo-Cell International, analysts believe Astrana Health is more attractive than Cryo-Cell International.

Cryo-Cell International has a beta of 0.659, which suggesting that the stock is 34.131% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.811%.

Cryo-Cell International has a quarterly dividend of $0.15 per share corresponding to a yield of 13.24%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Cryo-Cell International quarterly revenues are $7.9M, which are smaller than Astrana Health quarterly revenues of $620.4M. Cryo-Cell International's net income of $355.8K is lower than Astrana Health's net income of $6.7M. Notably, Cryo-Cell International's price-to-earnings ratio is 498.00x while Astrana Health's PE ratio is 35.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.27x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of 4.49% compared to Cryo-Cell International's net margin of 28%. Cryo-Cell International's return on equity of -- beat Biote's return on equity of --.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 73.12%. On the other hand Biote has an analysts' consensus of $6.40 which suggests that it could grow by 56.05%. Given that Cryo-Cell International has higher upside potential than Biote, analysts believe Cryo-Cell International is more attractive than Biote.

Cryo-Cell International has a beta of 0.659, which suggesting that the stock is 34.131% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International has a quarterly dividend of $0.15 per share corresponding to a yield of 13.24%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cryo-Cell International quarterly revenues are $7.9M, which are smaller than Biote quarterly revenues of $49M. Cryo-Cell International's net income of $355.8K is lower than Biote's net income of $13.7M. Notably, Cryo-Cell International's price-to-earnings ratio is 498.00x while Biote's PE ratio is 6.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.27x versus 0.72x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 4.49% compared to Cryo-Cell International's net margin of -2.6%. Cryo-Cell International's return on equity of -- beat Omnicell's return on equity of 1.73%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 73.12%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 55.99%. Given that Cryo-Cell International has higher upside potential than Omnicell, analysts believe Cryo-Cell International is more attractive than Omnicell.

Cryo-Cell International has a beta of 0.659, which suggesting that the stock is 34.131% less volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

Cryo-Cell International has a quarterly dividend of $0.15 per share corresponding to a yield of 13.24%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Cryo-Cell International quarterly revenues are $7.9M, which are smaller than Omnicell quarterly revenues of $269.7M. Cryo-Cell International's net income of $355.8K is higher than Omnicell's net income of -$7M. Notably, Cryo-Cell International's price-to-earnings ratio is 498.00x while Omnicell's PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.27x versus 1.14x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 4.49% compared to Cryo-Cell International's net margin of -5.49%. Cryo-Cell International's return on equity of -- beat P3 Health Partners's return on equity of -53.56%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 73.12%. On the other hand P3 Health Partners has an analysts' consensus of $8.00 which suggests that it could grow by 23.08%. Given that Cryo-Cell International has higher upside potential than P3 Health Partners, analysts believe Cryo-Cell International is more attractive than P3 Health Partners.

Cryo-Cell International has a beta of 0.659, which suggesting that the stock is 34.131% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International has a quarterly dividend of $0.15 per share corresponding to a yield of 13.24%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Cryo-Cell International quarterly revenues are $7.9M, which are smaller than P3 Health Partners quarterly revenues of $373.2M. Cryo-Cell International's net income of $355.8K is higher than P3 Health Partners's net income of -$20.5M. Notably, Cryo-Cell International's price-to-earnings ratio is 498.00x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.27x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.